{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:42:17Z","timestamp":1793400137620,"version":"4.5.0"},"reference-count":9,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,3]]},"DOI":"10.1182\/blood.2020008194","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T16:41:38Z","timestamp":1607013698000},"page":"2598-2600","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["BCL-2 inhibition in follicular lymphoma: can we tip the scales?"],"prefix":"10.1182","volume":"136","author":[{"given":"Nathan","family":"Fowler","sequence":"first","affiliation":[{"name":"MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020120310310098800_B1","article-title":"Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed\/refractory follicular lymphoma","author":"Zinzani","year":"2020","journal-title":"Blood"},{"key":"2020120310310098800_B2","first-page":"207","volume-title":"Follicular Lymphoma, Current Management and Novel Approaches. Cham","author":"Nastoupil","year":"2019"},{"issue":"4","key":"2020120310310098800_B3","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/cancers12040938","article-title":"BCL-2 proteins in pathogenesis and therapy of B-cell non-Hodgkin lymphomas","volume":"12","author":"Klanova","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2020120310310098800_B4","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fonc.2018.00636","article-title":"Targeting the Bcl-2 family in B cell lymphoma","volume":"8","author":"Adams","year":"2019","journal-title":"Front Oncol"},{"issue":"8","key":"2020120310310098800_B5","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020120310310098800_B6","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/annonc\/mdy256","article-title":"Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study","volume":"29","author":"de Vos","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"2020120310310098800_B7","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"key":"2020120310310098800_B8","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fonc.2018.00458","article-title":"Hematologic tumor cell resistance to the BCL-2 inhibitor venetoclax: a product of its microenvironment?","volume":"8","author":"Leverson","year":"2018","journal-title":"Front Oncol"},{"issue":"5","key":"2020120310310098800_B9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3324\/haematol.2015.139493","article-title":"Role of the tumor microenvironment in mature B-cell lymphoid malignancies","volume":"101","author":"Fowler","year":"2016","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/23\/2598\/1791144\/bloodbld2020008194c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/23\/2598\/1791144\/bloodbld2020008194c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T16:41:42Z","timestamp":1607013702000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/136\/23\/2598\/474272\/BCL2-inhibition-in-follicular-lymphoma-can-we-tip"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":9,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2020,12,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020008194","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,3]]}}}